Research ArticleCancer

Eradication of spontaneous malignancy by local immunotherapy

See allHide authors and affiliations

Science Translational Medicine  31 Jan 2018:
Vol. 10, Issue 426, eaan4488
DOI: 10.1126/scitranslmed.aan4488

Deliver locally, act globally

Mobilizing endogenous T cells to fight tumors is the goal of many immunotherapies. Sagiv-Barfi et al. investigated a combination therapy in multiple types of mouse cancer models that could provide sustainable antitumor immunity. Specifically, they combined intratumoral delivery of a TLR9 ligand with OX40 activation to ramp up T cell responses. This dual immunotherapy led to shrinkage of distant tumors and long-term survival of the animals, even in a stringent spontaneous tumor model. Both of these stimuli are in clinical trials as single agents and could likely be combined at great benefit for cancer patients.